Abstract
Background
Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35–0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.
Trial registration
ClinicalTrials.gov identifier: NCT01524783.
Patients and methods
Patients were randomized (2:1) to everolimus 10 mg/day or placebo, both with best supportive care. Subgroups of patients who received prior SSA, chemotherapy, or radiotherapy (including peptide receptor radionuclide therapy) were analyzed and reported.
Results
A total of 302 patients were enrolled, of whom, 163 (54%) had any prior SSA use (mostly for tumor control), 77 (25%) received chemotherapy, and 63 (21%) were previously exposed to radiotherapy. Patients who received everolimus had longer median PFS compared with placebo, regardless of previous SSA (with SSA: 11.1 vs 4.5 months [HR, 0.56 {95% CI, 0.37–0.85}]; without SSA: 9.5 vs 3.7 months [0.57 {0.36–0.89}]), chemotherapy (with chemotherapy: 9.2 vs 2.1 months [0.35 {0.19–0.64}]; without chemotherapy: 11.2 vs 5.4 months [0.60 {0.42–0.86}]), or radiotherapy (with radiotherapy: 9.2 vs 3.0 months [0.47 {0.24–0.94}]; without radiotherapy: 11 vs 5.1 months [0.59 {0.42–0.83}]) exposure. The most frequent drug-related adverse events included stomatitis (59%–65%), fatigue (27%–35%), and diarrhea (24%–34%) among the subgroups.
Conclusion
These results suggest that everolimus improves PFS in patients with advanced, progressive lung or GI NET, regardless of prior therapies. Safety findings were consistent with the known safety profile of everolimus in NET.
Plain language summary
As most patients with advanced, progressive neuroendocrine tumors will experience disease progression at some point during their treatment, an ongoing consideration of significant importance is the optimal sequence of treatment, which currently remains unknown. This post hoc analysis of the Phase III, randomized, placebo-controlled, RADIANT-4 study demonstrates that treatment with everolimus improved outcomes regardless of the use of prior therapies and suggests the potential for its use in both treatment-naive and previously treated patients with advanced, well-differentiated, progressive, nonfunctional neuroendocrine tumors of lung or gastrointestinal origin. In addition, safety of everolimus was generally consistent regardless of use of prior therapies.
Introduction
Neuroendocrine tumors (NET) are rare and a diverse group of neoplasms arising from neuroendocrine cells throughout the body, with the gastroenteropancreatic (GEP; ~57%) tract and the lungs (~27%) being the most common sites.Citation1,Citation2 Although considered rare, the annual incidence of NET has steadily increased over the past 4 decades from 1.09 per 100,000 in 1973 to 6.98 per 100,000 in 2012.Citation2,Citation3 NET are termed “functional” if they are associated with classical clinical symptoms (eg, carcinoid syndrome) due to hormonal hypersecretion, whereas those that do not exhibit symptoms are labeled as “nonfunctional” NET.Citation4 The majority of NET originating from the gastrointestinal (GI) tract and lung are nonfunctional. According to the Surveillance, Epidemiology, and End Results program, approximately half of patients have metastatic disease at the time of diagnosis, and 65% will die within 5 years of diagnosis.Citation2 The clinical course, management, and prognosis may vary widely and depend on multiple factors. These include disease-related factors, for example, primary tumor sites, histologic classification, resectability of the tumor, presence of metastatic disease, and presence of clinical symptoms and patient-related factors, for example, treatment goals, comorbidities, and treatment access. All of these factors should be taken into consideration when preparing a treatment plan for individual patients.Citation5
The treatment of inoperable, advanced NET is challenging due to limited therapeutic options. Although international guidelines have suggested potential treatment algorithms, the treatment of metastatic NET can vary widely based on patient factors as well as treatment centers due to lack of consensus for a single standard of care approach. Very few randomized controlled trials have been conducted in NET owing to the rarity of these tumors, and hence, the evidence supporting some treatment options is considered much weaker than for more common malignancies.Citation6 Patients with progressive NET of lung or GI tract have traditionally relied on somatostatin analogs (SSA), chemotherapy, and radiotherapy despite limited data from well-controlled, randomized clinical trials. SSA, such as octreotide and lanreotide, are the standard of care for symptom management in patients with functional NET.Citation7,Citation8 Furthermore, the antiproliferative effects of SSA have been confirmed in more recent prospective Phase III trials in patients with well-differentiated GEP-NET.Citation9,Citation10 Chemotherapy remained the only recommended therapeutic option in the treatment of advanced pancreatic NET (pNET) until the availability of novel targeted agents. Response rates reported from various retrospective studies of chemotherapy ranged from 25% to 42%.Citation11–Citation13 The benefit in response rate with chemotherapy did not translate to prolongation of PFS compared with historical controls, although such comparison is difficult in view of heterogeneity between studies and patient populations. In addition, significant cumulative toxicities associated with systemic chemotherapy use limit its long-term usage. Peptide receptor radionuclide therapy (PRRT) is an emerging treatment modality and could be a promising new treatment option for advanced, progressive somatostatin receptor-positive midgut NET.Citation14 However, its use remains investigational and limited information is available on long-term safety of PRRT.
In the past 6 years, everolimus (Afinitor, Novartis Pharmaceuticals Corporation [East Hanover, NJ, USA]; both as a single agent and in combination with long-acting octreotide) has demonstrated activity in the treatment of a broad spectrum of NET subtypes in various Phase II and III studies.Citation15–Citation20 In the recent Phase III, RADIANT-4 study, treatment with everolimus improved median progression-free survival (PFS) by 7.1 months and resulted in a 52% reduction in risk for disease progression or death (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.35–0.67; P<0.00001) compared with placebo in patients with advanced, nonfunctional, progressive lung or GI NET.Citation21 Everolimus showed consistent treatment benefits across all subgroups analyzed in the RADIANT-4 study; however, the impact of prior therapies on the activity of everolimus in this population is not known. This post hoc exploratory analysis was aimed to explore the effects of prior therapies (SSA, chemotherapy, and radiotherapy) on PFS in patients enrolled in the Phase III RADIANT-4 study and identify any impact of specific treatment sequences on outcomes of everolimus therapy for the treatment of individual patients with advanced NET.
Patients and methods
Study design
The RADIANT-4 trial was a prospective, double-blind, randomized, parallel-group, placebo-controlled, international, multicenter, Phase III study (ClinicalTrials.gov number NCT01524783). The detailed study design has been reported previously.Citation21 Patients were randomly assigned, in a 2:1 ratio, to receive everolimus 10 mg/day or placebo in combination with best supportive care. Treatment was continued until documented radiologic disease progression, development of an unacceptable adverse event (AE), initiation of new cancer therapy, or withdrawal of consent. Patients were prospectively stratified according to status with respect to prior SSA treatment (defined as continuous SSA for ≥12 weeks; receipt vs no receipt), tumor origin (based on prognostic level, grouped into 2 strata: 1) stratum A [better prognosis]: appendix, cecum, jejunum, ileum, duodenum, or NET of unknown primary; 2) stratum B [worse prognosis]: lung, stomach, colon [other than cecum] or rectum), and World Health Organization (WHO) performance status (0 vs 1) at baseline. Crossover was not permitted to open-label everolimus prior to primary PFS analysis if patients in placebo arm experienced disease progression.
In the current post hoc exploratory analysis of the RADIANT-4 study, patients were classified into the following subgroups based on whether they had received previous treatments with SSA, chemotherapy, or radiotherapy (including PRRT) at any time before study enrollment: prior SSA, no prior SSA, prior chemotherapy, no prior chemotherapy, prior radiotherapy, and no prior radiotherapy. The efficacy and safety of everolimus compared with placebo were assessed in each of these subgroups. Additional subgroups analyzed were the following: 1) everolimus as first-line treatment, which includes patients with no prior medical treatments (eg, SSA, chemotherapy, hormonal therapy, radiotherapy, targeted therapy) with or without prior surgery excluding other local surgeries (eg, biopsy, radiofrequency ablation, transarterial embolization, selective internal radiotherapy, percutaneous ethanol injection, and cryoablation); 2) everolimus as second-line treatment after prior SSA includes patients with only prior SSA and no other medical treatments (eg, chemotherapy, hormonal therapy, radiotherapy, targeted therapy) with or without prior surgery excluding other local surgeries.
Ethics
The protocol was reviewed and approved by an independent ethics committee or institutional review board (IRB) at each participating center and all patients gave written informed consent prior to participation. The list of each approving ethics committee and IRB is provided in . The study was conducted in accordance with Good Clinical Practice, the principles outlined in the Declaration of Helsinki, and local regulations.
Patient population
Adult patients (18 years or older) with histologically confirmed well-differentiated (grade 1 or 2 according to the 2010 WHO classification),Citation22 advanced, nonfunctional lung or GI NET and radiological documentation of disease progression within 6 months before randomization were eligible for inclusion. Additional key inclusion criteria included the presence of measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteriaCitation23 1.0 using multiphase computed tomography or magnetic resonance imaging for radiological assessment, WHO performance status of 1 or lower, and adequate bone marrow, renal, and hepatic function. Patients previously treated with SSA, interferon, one prior line of chemotherapy, and/or radiation therapy (including PRRT) were eligible for inclusion if disease progression was documented during or after their last treatment. It was also necessary for patients to have discontinued antineoplastic therapy for ≥4 weeks (6 months if PRRT) before randomization.
Patients were excluded if they had a history of or presented with carcinoid syndrome, poorly differentiated histology, or pNET. Concomitant SSA were permitted if the patients developed symptoms of carcinoid syndrome, which could not be managed by standard therapy (eg, loparamide). The change in functional status and the use of concomitant medications was documented. Patients who received >1 line of chemotherapy; prior therapy with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, or everolimus); hepatic intra-arterial embolization within 6 months, or cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization; or chronic treatment with corticosteroids or other immunosuppressive agents were also excluded.
Statistical analyses
In this post hoc exploratory analysis, efficacy assessments were conducted on the full analysis population, which was composed of all randomly assigned patients. All patients who received ≥1 dose of the study drug and who had ≥1 postbaseline safety evaluation were included in the safety population.
The median PFS as well as the 25th and 75th quartile were estimated using the Kaplan–Meier method and presented along with 95% CIs. HRs and corresponding 95% CIs were calculated using unstratified Cox proportional hazards model.
Results
Patient demographics and disposition
In the RADIANT-4 trial, 302 patients with advanced NET were randomly assigned to everolimus 10 mg/day (n=205) or placebo (n=97).Citation21 Both arms were comparable with respect to any prior SSA therapy (53% [n=109] of patients receiving everolimus vs 56% [n=54] receiving placebo; mostly for tumor control), chemotherapy (26% [n=54] vs 24% [n=23]), and radiotherapy (21% [n=44] vs 20% [n=19]). Prior radiotherapy arm also included PRRT (n=19; 15 patients in everolimus and 4 in placebo arm). A total of 5 patients (4 in everolimus and 1 in placebo arm) received concomitant SSA. A change in functional status was observed in 17 patients (10 in everolimus arm and 7 in placebo arm).
Baseline demographics and clinical characteristics of patients in different subgroups were similar (). Overall, the primary tumor sites were GI (58% of patients; including ileum, rectum, jejunum, stomach, colon, duodenum, cecum, appendix, and other sites identified by investigators as GI), lung (31%), and NET of unknown primary (11%). The GI subgroup was further categorized into midgut NET (38% of patients; included primary tumors originating in the duodenum, small intestine [ileum and jejunum], cecum, appendix, and other origins identified by investigators as GI, mostly from small intestine) and non-midgut NET (20% of patients; primary tumors originating from stomach, colon, and rectum). More than 60% of patients had well-differentiated (grade 1) disease, >70% had WHO performance status of very good (ie, zero [0]), and the majority (80%) had liver involvement.
Table 1 Patient demographics and baseline characteristics by prior therapies use
A total of 163 patients received prior SSA for any duration (most common SSA received were long-acting octreotide in 126 patients and lanreotide autogel in 23 patients). The median duration of prior exposure to SSA in all patients was 15.0 months (range, <0.1–103.5) and was similar in both treatment arms (). A total of 105 patients (everolimus arm [n=69]; placebo arm [n=36]) had GI as the primary tumor site in the prior SSA subgroup. The median duration of exposure to prior SSA in patients with GI NET was 16.7 months (range, 0–103.5) and was longer in the everolimus arm (21.2 months) vs placebo (14.1 months). Only 25 patients (21 from everolimus arm and 4 in the placebo) in the prior SSA group were treatment-naive and did not receive any other antineoplastic treatments except SSA.
Table 2 Prior SSA exposure by study treatment (full analysis set)
Of the 157 patients who received prior SSA continuously for at least 12 weeks, 96 had GI as primary tumor origin, which included 67 patients with midgut NET and 29 with non-midgut NET.
Eighty-five patients received everolimus as a first-line treatment, which include patients with no prior medical treatments (eg, SSA, chemotherapy, hormonal therapy, radiotherapy, targeted therapy) with or without prior surgery excluding other local surgeries. The number of patients who received everolimus as second-line treatment after prior SSA (only SSA with or without prior surgery excluding other local surgeries) was 78.
Efficacy
As summarized in and shown in , median PFS in everolimus arm was superior to placebo arm in all subgroups.
Figure 1 Progression-free survival by central review (full analysis set).
Abbreviations: CI, confidence interval; HR, hazard ratio; SSA, somatostatin analogs.
Table 3 Progression-free survival by central review (full analysis set)
Among patients who received prior SSA for any duration, median PFS assessed by central review was 11.1 months (95% CI, 9.2–13.3) in the everolimus arm vs 4.5 months (3.6–7.9) in the placebo arm. Everolimus was associated with a 44% reduction in the estimated risk of progression (HR, 0.56; 95% CI, 0.37–0.85) in patients who received prior SSA. Among those patients who did not receive prior SSA, the median PFS in the everolimus arm was 9.5 months (95% CI, 8.2–16.7) vs 3.7 months (2.4–8.1) in the placebo, with a 43% reduction in the estimated risk for progression (HR, 0.57; 95% CI, 0.36–0.89).
Additionally, in the prior SSA subgroup, among patients who continuously received prior SSA for at least 12 weeks, median PFS (everolimus vs placebo; central review) was 11.2 months (95% CI, 9.2–17.3) vs 4.5 months (3.6–7.9) in the GI, 16.6 months (9.2–21.2) vs 7.4 months (3.7–16.7), in the midgut and 5.6 months (3.8–12.7) vs 1.9 months (1.6–4.5) in the non-midgut NET subgroups, respectively.
For patients who were previously treated with chemotherapy, the median PFS was 9.2 (95% CI, 5.6–11.7) vs 2.1 months (1.9–3.7) with everolimus and placebo, respectively, with a 65% reduction in the estimated risk for progression (HR, 0.35; 95% CI, 0.19–0.64) in the prior chemotherapy subgroup. In the chemo-naive patients, the median PFS for everolimus was 11.2 months (95% CI, 9.2–16.6) vs 5.4 months (3.7–9.0) for placebo, with a 40% reduction in the estimated risk for progression (HR, 0.60; 95% CI, 0.42–0.86).
In the prior radiotherapy subgroup, centrally assessed median PFS was 9.2 months (95% CI, 5.6–20.9) for everolimus vs 3.0 months (1.9–7.9) for placebo, corresponding to a 53% reduction in the estimated risk for progression (HR, 0.47; 95% CI, 0.24–0.94). Among patients who did not receive prior radiotherapy, the median PFS also remained longer with everolimus vs placebo (11.0 months [95% CI, 9.2–13.9] vs 5.1 months [3.6–8.1], respectively) resulting in a 41% reduction in the estimated risk for progression (HR, 0.59; 95% CI, 0.42–0.83).
As reported in , everolimus as a first-line treatment was superior to placebo in treatment-naive patients who did not receive any prior medical treatments except surgery. Everolimus had substantially reduced the risk of disease progression or death (HR =0.38 [95% CI, 0.21–0.71]) as a second-line treatment option in patients who received only prior SSA and no other antineoplastic therapies.
Table 4 Progression-free survival and best overall response (central review) of everolimus in different lines of treatment
The response waterfall plot for patients who did and did not receive prior therapy is shown in . Everolimus was associated with a higher disease control rate compared with placebo (ranged from 75% to 87% in everolimus arm vs 44% to 73% in placebo arm; ).
Figure 2 Percentage change from baseline in size of target lesion, central review (full analysis set).
Abbreviations: PD, progressive disease; SSA, somatostatin analogs.
Table 5 Best overall response by central review
Safety
As shown in , the incidence of AEs was not substantially influenced by the type of prior therapy, except for asthenia and dyspnea, which were substantially higher in patients with prior chemotherapy and prior radiotherapy, respectively. The safety profile of everolimus generally remained comparable in patients previously treated with PRRT (n=15) vs no prior PRRT, with the exception of a higher incidence of grade 3 to 4 neutropenia (13% vs 1%), noninfectious pneumonitis (7% vs 1%), edema (7% vs 2%), and thrombocytopenia (7% vs 1%) observed in the everolimus arm (). Most reported AEs were grade 1 or 2. The most common drug-related AEs occurring with a frequency ≥10% are listed in and included stomatitis, diarrhea, fatigue, infections, rash, and peripheral edema.
Table 6 Drug-related adverse events reported by ≥10% of the patients
Table 7 Drug-related adverse events reported by ≥10% of the patients with respect to prior PRRT
Discussion
Primary results of the RADIANT-4 study reported a statistically significant prolongation of median PFS by 7.1 months with everolimus compared with placebo (HR, 0.48; P<0.00001) and a 52% reduction of risk in PFS in patients with advanced, well-differentiated, progressive, nonfunctional NET of lung or GI origin.Citation21 In this post hoc exploratory analysis of RADIANT-4 study, we observed a consistent benefit in PFS among patients receiving everolimus compared with placebo irrespective of the use of prior therapies. Everolimus improved the median PFS by 5.8 months to a total of 8 months and contributed to a 40%–65% reduction in relative risk of disease progression or death compared with placebo in subgroups of patients receiving different prior therapies. Everolimus, used in second-line treatment, substantially prolonged the median PFS by 9.4 months in patients who received only prior SSA.
Recent scientific advancements and results from several pivotal clinical trials have transformed our understanding of NET and have changed the treatment paradigm. As the number of available treatment options is increasing for patients with advanced NET, it will become of critical importance to select the treatment based on multiple factors. In addition, since most patients will experience disease progression at some point, an important consideration will be the optimal treatment sequence for these patients, which is currently unknown.
Current evidence-based treatment options for NET include SSA, the mTOR inhibitor everolimus, the multiple tyrosine kinase inhibitor (TKI) sunitinib and PRRT with 177Lu-Dotatate. SSA have been an established treatment option since 1980 for effective management of carcinoid syndrome in functional NET. More recently, in 2 placebo-controlled Phase III trials, SSA have also demonstrated antiproliferative activity in patients with low-grade (grade 1) midgut NETCitation10 and in patients with low- to intermediate-grade (Ki-67<10%) enteropancreatic NET.Citation9 Although SSA were not investigated in gastric or lung NET and their effect remains unclear, SSA use in the absence of any approved drugs could be justified if the tumor is of low grade and expresses the somatostatin receptors (SSTR).Citation24 In addition, SSA have also demonstrated a long-term favorable safety profile, and hence, may qualify as a first-line therapy in different types of NET.Citation9,Citation10,Citation25
Until the availability of novel targeted therapeutic agents in 2011, streptozotocin-based chemotherapy, either in combination with 5-fluorouracil or doxorubicin was an established treatment option for advanced pNET. Different retrospective studies have reported response rates ranging from 25% to 42% that support streptozotocin-based chemotherapy activity in the era of novel targeted drugs, particularly in grade 2 (G2) progressive pNET with higher tumor burden.Citation11–Citation13 Temozolomide-based chemotherapy, either as monotherapy or in combination with capecitabine or bevacizumab is an alternative regimen in pNET based on the data from limited number of retrospective studies with response rates of 30%–70%.Citation26 There is very little evidence to support the use of chemotherapy in non-pNET.Citation27
PRRT utilizing various radionuclides such as 111Indium, 90Yttrium, and 177Lutetium, has been used for 15 years in many and mostly single-center uncontrolled trials in different types of NET; however, recently, in the first randomized controlled Phase III NETTER-1 trial, 177Lu-Dotatate in combination with long-acting octreotide demonstrated a significant prolongation of PFS compared with high-dose octreotide (60 mg/month) in patients with advanced midgut NET.Citation14 The expression of SSTR is an essential criterion for the administration of PRRT, and hence, its use remains limited to a selected subgroup of patients. In addition, there is an increased risk for long-term renal and bone marrow toxicity, as well as a low risk for development of therapy-related myeloid neoplasms.Citation28,Citation29
Currently, approved targeted drugs in NET are sunitinib and everolimus. Everolimus has been more extensively studied in NET and has demonstrated activity across a broad range of NET subtypes from lung to the rectum.Citation20,Citation21 Sunitinib is an approved therapy in progressive pNET.Citation30 Despite some efficacy of novel TKIs (pazopanib, axitinib, cabozantinib) reported in Phase II trials, there is no definite evidence of efficacy of TKIs in NET of non-pancreatic origin.Citation31
The safety and tolerability of everolimus in this present subgroup analysis are consistent with the overall RADIANT-4 study population. The most frequent AEs reported with everolimus were grade 1 to 2 in severity and included stomatitis, diarrhea, fatigue, infections, rash, and peripheral edema. No new safety signals were observed that would preclude its use in patients who received specific prior therapies and most of the everolimus-related AEs were manageable through dose modification or interruption without altering the duration of treatment. As suggested by Berardi et al in a small, retrospective study of 116 patients, cumulative dose and dose intensity of everolimus are prognostic factors for efficacy, and hence, everolimus treatment should be continued in patients who are responding to everolimus despite delays or treatment interruptions.Citation32 A population-based, retrospective, multicenter study from Italy suggested that everolimus use after PRRT and/or cytotoxic chemotherapy may increase the overall toxicity of everolimus.Citation33 In this analysis, the greater incidence of grade 3 to 4 neutropenia, noninfectious pneumonitis, edema, and thrombocytopenia reported in the prior PRRT subgroup of this study may be related to prior use of PRRT. In general, the safety profile of everolimus in this analysis was comparable, regardless of specific prior therapies, including PRRT (although the numbers of patients who received prior PRRT were very small [n=15]) and had a similar safety profile to a smaller retrospective study from the Netherlands.Citation34
It is important to note several limitations of the present analysis, including the small sample size for some of the subgroups, the imbalanced patient numbers between treatment groups, and the retrospective nature of the evaluation. However, consistent improvements in PFS with everolimus were observed across all subgroups similar to primary results of the RADIANT-4 study. As an exploratory analysis, it is not powered to support conclusions regarding treatment outcomes, and hence, the results should be considered with caution.
Currently, due to the lack of definite treatment predictors, treatment decisions are made by clinical judgment and pathological criteria. Newer evidence-based treatment strategies have changed the treatment landscape for NET, but the ideal treatment sequence that can be provided to patients remains unknown.
Conclusion
Given the growing number of therapeutic options becoming available, it is important to select therapies based on treatment goals individualized to the patient. The present RADIANT-4 subanalysis demonstrates that everolimus improved outcomes for patients with advanced, progressive, nonfunctional lung or GI NET regardless of the use of prior therapies and suggests the potential for its use in treatment-naive and previously treated patients. The safety profile of everolimus was not impacted by the use of prior therapies and was similar to that reported for the overall analysis population.
Author contributions
Study concept and design: James C Yao, Nicola Fazio, Simron Singh, Jonathan Strosberg, Fabian Herbst, and Marianne E Pavel. Provision of study material or patients: Roberto Buzzoni, Carlo Carnaghi, Jonathan Strosberg, Nicola Fazio, Simron Singh, Marianne E Pavel, Edward M Wolin, Juan W Valle, Do-Youn Oh, James C Yao, and Rodney Pommier. Statistical analysis: Antonia Ridolfi. All authors contributed toward data interpretations, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Acknowledgments
We thank all the investigators and their patients for their participation in the study. We thank Rohit Kachhadiya, M. Pharm, (Novartis Healthcare Pvt. Ltd.) for providing medical editorial assistance with this manuscript. This study was funded by Novartis Pharmaceuticals Corporation. This study was presented in part at the European Neuroendocrine Tumor Society (ENETS) conference, Barcelona, Spain; March 9 to 11, 2016.
Supplementary material
Table S1 List of independent ethics committees (IECs) or institutional review boards (IRBs) by study center
Disclosure
The authors report the following types of declarations of interest: consultant/advisory relationship (C/A), employment (E), honoraria received (H), intellectual property rights/inventor/patent holder (IP), leadership position (L), ownership interest (OI), research funding (RF), speaker’s bureau (SB), and travel and accommodation expenses (TAE). Roberto Buzzoni: Italfarmaco, Novartis, Otsuka (RF); Ipsen, Italfarmaco, Novartis (TAE); Jonathan Strosberg: Novartis (H); Ipsen, Lexicon, Novartis (C/A); Novartis, Pfizer (RF); Bayer, Genentech (SB); Nicola Fazio: Ipsen, Novartis (H); Ipsen, Lexicon, Novartis, Italfarmaco (C/A); Novartis (RF); Ipsen, Novartis (TAE); Simron Singh: Novartis (H, C/A, TAE, RF); Fabian Herbst: Novartis (E, OI); Antonia Ridolfi: Novartis (E); Marianne E Pavel: Ipsen, Lexicon, Novartis, Pfizer (H); Ipsen, Lexicon, Novartis, Pfizer (C/A); Novartis (RF); Ipsen, Novartis (TAE); Edward M Wolin: Celgene, Ipsen, Novartis (C/A); Juan W Valle: Novartis (H, C/A, RF); James C Yao: Ipsen, Lexicon, Novartis (C/A); Novartis (RF); Rodney Pommier: Novartis, Pfizer, Ipsen, Lexicon (C/A); Novartis, Ipsen, Lexicon (TAE). The other authors report no conflicts of interest in this work.
References
- MaggardMAO’ConnellJBKoCYUpdated population-based review of carcinoid tumorsAnn Surg2004240111712215213627
- YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
- ShenCDasariAZhaoBIncidence and prevalence of neuroendocrine tumors in the United States 1973–2012. abstr 121 presented at NANETS 2016
- VinikAIWolteringEAWarnerRRNANETS consensus guidelines for the diagnosis of neuroendocrine tumorPancreas201039671373420664471
- KunzPLReidy-LagunesDAnthonyLBConsensus guidelines for the management and treatment of neuroendocrine tumorsPancreas201342455757723591432
- WongMHChanDLLeeASystematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET)PLoS One2016116e015814027362760
- BajettaEProcopioGCatenaLLanreotide Autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III studyCancer2006107102474248117054107
- JansonETWestlinJEErikssonBAhlstromHNilssonSObergK[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatmentEur J Endocrinol199413165775817804439
- CaplinMEPavelMCwiklaJBLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
- RinkeAMullerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
- Clewemar AntonodimitrakisPSundinAWassbergCGranbergDSkogseidBErikssonBStreptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prog-nostic factors and toxicityNeuroendocrinology20161033–434535326279284
- DilzLMDeneckeTSteffenIGStreptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumoursEur J Cancer201551101253126225935542
- KrugSBochMDanielHStreptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms-predictive and prognostic markers for treatment stratificationPLoS One20151012e014382226630134
- StrosbergJEl-HaddadGWolinEPhase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
- CastellanoDBajettaEPanneerselvamAEverolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyOncologist2013181465323263288
- FazioNGranbergDGrossmanAEverolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 studyChest2013143495596223187897
- ItoTOkusakaTIkedaMEverolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trialJpn J Clin Oncol2012421090391122859827
- PavelMEHainsworthJDBaudinEEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496
- YaoJCLombard-BohasCBaudinEDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol2010281697619933912
- YaoJCShahMHItoTEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med2011364651452321306238
- YaoJCFazioNSinghSEverolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyLancet20163871002296897726703889
- KlimstraDSModlinIRCoppolaDLloydRVSusterSThe pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systemsPancreas201039670771220664470
- TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
- PavelMO’TooleDCostaFENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary siteNeuroendocrinology2016103217218526731013
- ModlinIMPavelMKiddMGustafssonBIReview article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAliment Pharmacol Ther201031216918819845567
- KoumarianouAKaltsasGKulkeMHTemozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspectsNeuroendocrinology2015101427428825924937
- LamarcaAElliottEBarriusoJChemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause?Cancer Treat Rev201644264126855376
- BodeiLKwekkeboomDJKiddMModlinIMKrenningEPRadiolabeled somatostatin analogue therapy of gastroenteropancreatic cancerSemin Nucl Med201646322523827067503
- BodeiLModlinIMLusterMMyeloid neoplasms after chemotherapy and PRRT: myth and realityEndocr Relat Cancer2016238C1C727353035
- RaymondEDahanLRaoulJLSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
- PhanATHalperinDMChanJAPazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 studyLancet Oncol201516669570325956795
- BerardiRTorniaiMPuscedduSPrognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumorsCancer Med2017671493149928547856
- PanzutoFRinzivilloMFazioNReal-world study of everolimus in advanced progressive neuroendocrine tumorsOncologist201419996697425117065
- KampKGumzBFeeldersRASafety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotateEndocr Relat Cancer201320682583124036133